Research programme: anti-PSGL-1 monoclonal antibody - Novartis

Drug Profile

Research programme: anti-PSGL-1 monoclonal antibody - Novartis

Alternative Names: Anti P-selectin glycoprotein ligand-1; Anti-PSGL-1-mAb - Novartis; SELK-2

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Cytovance Biologics; Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P-selectin ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • No development reported Crohn's disease

Most Recent Events

  • 21 Nov 2016 Selexys Pharmaceuticals has been acquired and merged into Novartis
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in USA (Parenteral)
  • 06 May 2014 Preclinical trials in Multiple myeloma in USA (Parenteral) before May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top